Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 6;59(1):2102002.
doi: 10.1183/13993003.02002-2021. Print 2022 Jan.

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Jiuyang Xu  1   2   3 , Bin Cao  4   3   5
Affiliations
Editorial

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Jiuyang Xu et al. Eur Respir J. .

Abstract

Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda. https://bit.ly/3iaNBsB

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Xu has nothing to disclose. Conflict of interest: B. Cao has nothing to disclose.

Comment on

  • Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial.
    Sivapalan P, Ulrik CS, Lapperre TS, Bojesen RD, Eklöf J, Browatzki A, Wilcke JT, Gottlieb V, Håkansson KEJ, Tidemandsen C, Tupper O, Meteran H, Bergsøe C, Brøndum E, Bødtger U, Bech Rasmussen D, Graff Jensen S, Pedersen L, Jordan A, Priemé H, Søborg C, Steffensen IE, Høgsberg D, Klausen TW, Frydland MS, Lange P, Sverrild A, Ghanizada M, Knop FK, Biering-Sørensen T, Lundgren JD, Jensen JS; ProPAC-COVID writing group on behalf of the ProPAC-COVID Study Group. Sivapalan P, et al. Eur Respir J. 2022 Jan 6;59(1):2100752. doi: 10.1183/13993003.00752-2021. Print 2022 Jan. Eur Respir J. 2022. PMID: 34083403 Free PMC article. Clinical Trial.

References

    1. Ben-Zvi I, Kivity S, Langevitz P, et al. . Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153. doi:10.1007/s12016-010-8243-x - DOI - PMC - PubMed
    1. Barnard DL, Day CW, Bailey K, et al. , Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother 2006; 17: 275–284. doi:10.1177/095632020601700505 - DOI - PubMed
    1. Keyaerts E, Li S, Vijgen L, et al. . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416–3421. doi:10.1128/AAC.01509-08 - DOI - PMC - PubMed
    1. Keyaerts E, Vijgen L, Maes P, et al. . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264–268. doi:10.1016/j.bbrc.2004.08.085 - DOI - PMC - PubMed
    1. Niu J, Shen L, Huang B, et al. . Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res 2020; 173: 104646. doi:10.1016/j.antiviral.2019.104646 - DOI - PMC - PubMed

LinkOut - more resources